Nuvectis Pharma Inc

For the period ended Dec 31, 2024. Filed Feb 25, 2025.

About this filing

A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.

FY2024 · Filed Feb 25, 2025

NVCT$21.08+0.3%Stored close · as of Nov 10, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits

Contents

Balance Sheets as of December 31, 2024 and 2023

BALANCE SHEETS


· · December 31,
	2024		2023
Assets
CURRENT ASSETS · ·
Cash and cash equivalents		$18,533		$19,126
Other current assets		74		59
TOTAL CURRENT ASSETS		18,607		19,185

TOTAL ASSETS		$18,607		$19,185

Liabilities and Shareholders’ Equity

CURRENT LIABILITIES
Accounts payables		$2,498		$2,771
Accrued liabilities		840		415
Employee compensation and benefits		5,556		3,798
TOTAL CURRENT LIABILITIES		8,894		6,984
TOTAL LIABILITIES		8,894		6,984

COMMITMENTS AND CONTINGENCIES, see Note 5

SHAREHOLDERS’ EQUITY, see Note 6
Common Shares, $0.00001 par value – 60,000,000 shares authorized as of December 31, 2024, and December 31, 2023, 19,495,683, and 17,418,886 shares issued and outstanding as of December 31, 2024 and December 31, 2023, respectively		*		*
Additional paid in capital		82,958		66,446
Accumulated deficit		(73,245)		(54,245)
TOTAL SHAREHOLDERS’ EQUITY		9,713		12,201
TOTAL LIABILITIES AND SHAREHOLDERS’ EQUITY		$18,607		$19,185

*Represent amount lower than $1,000 USD.

ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.